Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease

E. R. Siemers, J. F. Quinn, J. Kaye, M. R. Farlow, A. Porsteinsson, P. Tariot, P. Zoulnouni, J. E. Galvin, D. M. Holtzman, D. S. Knopman, J. Satterwhite, C. Gonzales, R. A. Dean, P. C. May

Research output: Contribution to journalArticle

275 Scopus citations

Abstract

LY450139 dihydrate, a γ-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Aβ1-40 in plasma decreased by 38.2%; in CSF, Aβ1-40 decreased by 4.42 ± 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Aβ concentrations and a measurable decrease in CSF Aβ.

Original languageEnglish (US)
Pages (from-to)602-604
Number of pages3
JournalNeurology
Volume66
Issue number4
DOIs
StatePublished - Feb 1 2006

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease'. Together they form a unique fingerprint.

  • Cite this

    Siemers, E. R., Quinn, J. F., Kaye, J., Farlow, M. R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J. E., Holtzman, D. M., Knopman, D. S., Satterwhite, J., Gonzales, C., Dean, R. A., & May, P. C. (2006). Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology, 66(4), 602-604. https://doi.org/10.1212/01.WNL.0000198762.41312.E1